col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


64 Results       Page 1

 [1] 
SAGE Publications: Multiple Sclerosis Journal
  original article Date Title Authors   All Authors
1 [GO] 2025―Jan―03 Post-acute sequela of COVID-19 infection in individuals with multiple sclerosis Amber Salter, Samantha Lancia, Gary R Cutter, Robert J Fox, Ruth Ann Marrie
2 [GO] 2024―Nov―09 Secondary organising pneumonia associated to COVID-19 infection in patients with central nervous system inflammatory demyelinating diseases treated with anti-CD20 therapies René Carvajal, Breogán Rodríguez-Acevedo, Lorena García-Vasco, Ana Zabalza, Helena Ariño, Luca Bollo, et al. (+28)
3 [GO] 2024―Mar―08 Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis Maria Grazia Aprea, Irene Schiavetti, Emilio Portaccio, Chiara Ballerini, Simona Bonavita, Maria Buscarinu, et al. (+25)
4 [GO] 2024―Feb―26 The impact of social distancing measures on anti-JC virus serostatus changes before and during the COVID-19 pandemic in US patients with multiple sclerosis Stephen C Krieger, Susie Sinks, Furong Huang, Julie Steverson, Tamar J Kalina, Kurt White, Robin L Avila
5 [GO] 2024―Jan―22 COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022 Lina Jeantin, Edouard Januel, Pierre Labauge, Elisabeth Maillart, Jérôme de Seze, Hélène Zéphir, et al. (+24)
6 [GO] 2023―Nov―09 Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod Zoé LE van Kempen, Koos PJ van Dam, Jim BD Keijser, Eileen W Stalman, Laura YL Kummer, Eva MM Strijbis, et al. (+8)
7 [GO] 2023―Sep―30 Differential effects of selective versus unselective sphingosine 1-phosphate receptor modulators on T- and B-cell response to SARS-CoV-2 vaccination Undine Proschmann, Magdalena Mueller-Enz, Christina Woopen, Georges Katoul Al Rahbani, Rocco Haase, Anja Dillenseger, et al. (+4)
8 [GO] 2023―Aug―26 Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton’s tyrosine kinase inhibitor Amit Bar-Or, Anne H Cross, Anthony L Cunningham, Yann Hyvert, Andrea Seitzinger, Hans Gühring, et al. (+4)
9 [GO] 2023―Jul―11 Vaccine-breakthrough SARS-CoV-2 infections in people with multiple sclerosis and related conditions: An observational study by the New York COVID-19 Neuro-Immunology Consortium (NYCNIC-2) Sylvia Klineova, Rebecca Straus Farber, Tracy DeAngelis, Tungming Leung, Tyler Smith, Richard Blanck, et al. (+2)
10 [GO] 2023―Jul―11 Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination Safiya A Zaloum, Callum H Wood, Pooja Tank, Matthew Upcott, Nicola Vickaryous, Valerie Anderson, et al. (+19)
11 [GO] 2023―Jul―11 Breakthrough COVID-19 infection in people with MS after SARS-CoV-2 vaccination: Should we still be concerned? Zoé LE Van Kempen, Valentina Mazziotti
12 [GO] 2023―Jun―16 Impact of COVID-19 vaccination or infection on disease activity in a radiologically isolated syndrome cohort: The VaxiRIS study Mikael Cohen, Océane Thomel-Rocchi, Aksel Siva, Darin T Okuda, Rana Karabudak, Hüsnü Efendi, et al. (+20)
13 [GO] 2023―May―26 Sars-CoV2 infection in pregnant women with multiple sclerosis Maria Grazia Aprea, Irene Schiavetti, Emilio Portaccio, Chiara Ballerini, Mario Alberto Battaglia, Roberto Bergamaschi, et al. (+49)
14 [GO] 2023―May―11 Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs Rocco Capuano, Luca Prosperini, Manuela Altieri, Lorena Lorefice, Roberta Fantozzi, Paola Cavalla, et al. (+18)
15 [GO] 2023―Mar―28 Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20-treated patients with multiple sclerosis after three or four COVID-19 vaccinations Carolin Otto, Tatjana Schwarz, Lara M Jeworowski, Marie L Schmidt, Felix Walper, Florence Pache, et al. (+7)
16 [GO] 2023―Mar―24 Characteristics of pediatric patients with multiple sclerosis and related disorders infected with SARS-CoV-2 Teri Schreiner, Molly Wilson-Murphy, Jan Mendelt-Tillema, Michael Waltz, Rachel Codden, Leslie Benson, et al. (+15)
17 [GO] 2023―Feb―25 Acute central nervous system inflammation following COVID-19 vaccination: An observational cohort study Sydney Lee, Alexandra Muccilli, Raphael Schneider, Daniel Selchen, Kristen M Krysko
18 [GO] 2023―Feb―07 Humoral COVID-19 vaccine response in patients with NMOSD/MOGAD during anti-IL-6 receptor therapy compared to other immunotherapies Carolin Schwake, Thivya Pakeerathan, Ingo Kleiter, Marius Ringelstein, Orhan Aktas, Mirjam Korporal-Kuhnke, et al. (+18)
19 [GO] 2023―Feb―01 Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and meta-analysis Maria-Ioanna Stefanou, Lina Palaiodimou, Aikaterini Theodorou, Maria Veatriki Christodoulou, John S Tzartos, Dimitrios Tzanetakos, et al. (+11)
20 [GO] 2022―Nov―28 T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy Anthony T Reder, Olaf Stuve, Stephanie K Tankou, Thomas P Leist
21 [GO] 2022―Jul―13 A disproportionality analysis for the association of central nervous system demyelinating diseases with COVID-19 vaccination using the World Health Organization pharmacovigilance database Jee-Eun Kim, Jin Park, Tae-Jin Song
22 [GO] 2022―Jun―28 Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study Federica Magnè, Maria Cellerino, Elisa Balletto, Kenda Aluan, Matilde Inglese, Malgorzata Mikulska, Matteo Bassetti
23 [GO] 2022―Jun―23 Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies Irene Schiavetti, Cinzia Cordioli, Maria Laura Stromillo, Maria Teresa Ferrò, Alice Laroni, Eleonora Cocco, et al. (+23)
24 [GO] 2022―May―19 Two years of COVID-19 in the MS community: What have we learnt so far? Ana Zabalza, Alan J Thompson, Xavier Montalban
25 [GO] 2022―May―18 Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis Tatjana Schwarz, Carolin Otto, Terry C Jones, Florence Pache, Patrick Schindler, Moritz Niederschweiberer, et al. (+4)
26 [GO] 2022―Apr―27 Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases? Ana Zabalza, Georgina Arrambide, Susana Otero-Romero, Agustín Pappolla, Paula Tagliani, Samuel López-Maza, et al. (+37)
27 [GO] 2022―Apr―27 Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study Giovanna S Manzano, Dylan R Rice, Eric C Klawiter, Marcelo Matiello, Rebecca L Gillani, Shahamat S Tauhid, et al. (+2)
28 [GO] 2022―Feb―12 Clinical commentary MSJ-21-064 MOG antibody-associated longitudinal extensive myelitis after Oxford-Astra Zeneca’s COVID-19 vaccination Sarah Wright
29 [GO] 2022―Jan―07 Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions Jeffrey A Cohen, Robert A Bermel, Cynthia I Grossman, Carrie M Hersh, Megan Hyland, Ellen M Mowry, et al. (+10)
30 [GO] 2021―Dec―21 Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica Edouard Januel, Jérôme De Seze, Patrick Vermersch, Elisabeth Maillart, Bertrand Bourre, Julie Pique, et al. (+7)
31 [GO] 2021―Dec―21 MOG-antibody-associated longitudinal extensive myelitis after ChAdOx1 nCoV-19 vaccination Larissa Dams, Markus Kraemer, Jana Becker
32 [GO] 2021―Nov―16 Keep your eyes on the prize: Tackling breakthrough COVID-19 in MS patients Zoé LE van Kempen, Joep Killestein, Hans-Peter Hartung
33 [GO] 2021―Oct―01 Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study Gabriel Bsteh, Sophie Dürauer, Hamid Assar, Harald Hegen, Bettina Heschl, Fritz Leutmezer, et al. (+10)
34 [GO] 2021―Oct―01 Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients Zoya G Georgieva, Rainer Dӧffinger, Dinakantha Kumararatne, Alasdair J Coles, Claire McCarthy
35 [GO] 2021―Sep―30 Demyelinating disorders following COVID-19 vaccination Marcello Moccia
36 [GO] 2021―Sep―30 ADEM after ChAdOx1 nCoV-19 vaccine: A case report Virginia Rinaldi, Gianmarco Bellucci, Andrea Romano, Alessandro Bozzao, Marco Salvetti
37 [GO] 2021―Aug―13 SARS-CoV-2 antibodies in multiple sclerosis patients depending on the vaccine mode of action? Paulus S Rommer, Gabriel Bsteh, Thomas Berger, Uwe Klaus Zettl
38 [GO] 2021―Jul―30 SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study Maria Pia Sormani, Irene Schiavetti, Doriana Landi, Luca Carmisciano, Nicola De Rossi, Cinzia Cordioli, et al. (+15)
39 [GO] 2021―Jul―27 COVID-19 vaccine hesitancy in multiple sclerosis: A cross-sectional survey Lauren Uhr, Farrah J Mateen
40 [GO] 2021―Jul―09 Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic Zoë YGJ van Lierop, Alyssa A Toorop, Wouter JC van Ballegoij, Tom BG Olde Dubbelink, Eva MM Strijbis, Brigit A de Jong, et al. (+6)
41 [GO] 2021―Jul―02 Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry Tim Spelman, Lars Forsberg, Kyla McKay, Anna Glaser, Jan Hillert
42 [GO] 2021―Jun―08 Late-onset cutaneous reaction to BNT162b2 mRNA COVID-19 vaccine in an immunocompromised patient Bianca Weinstock-Guttman, Dejan Jakimovski
43 [GO] 2021―Jun―04 Mental health of people with multiple sclerosis during the COVID-19 outbreak: A prospective cohort and cross-sectional case-control study of the UK MS Register Afagh Garjani, Rachael Hunter, Graham R Law, Rodden M Middleton, Katherine A Tuite-Dalton, Ruth Dobson, et al. (+9)
44 [GO] 2021―Apr―15 COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021 Anat Achiron, Mark Dolev, Shay Menascu, Daniela-Noa Zohar, Sapir Dreyer-Alster, Shmuel Miron, et al. (+9)
45 [GO] 2021―Mar―25 Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey Emilio Portaccio, Mattia Fonderico, Bernhard Hemmer, Tobias Derfuss, Bruno Stankoff, Krzysztof Selmaj, et al. (+2)
46 [GO] 2021―Feb―02 Incidence and clinical outcome of Coronavirus disease 2019 in a cohort of 11,560 Brazilian patients with multiple sclerosis
47 [GO] 2020―Nov―18 COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments Alice Laroni, Irene Schiavetti, Maria Pia Sormani, Antonio Uccelli
48 [GO] 2020―Oct―16 Lymphocyte counts and the risk of COVID-19 in people with MS Nikos Evangelou, Afagh Garjani
49 [GO] 2020―Oct―16 Response to letter ‘Lymphocyte counts and the risk of COVID-19 in people with MS’ Floor C Loonstra, Zoé LE van Kempen, Eva M Strijbis, Joep Killestein, Elske Hoitsma, Jop P Mostert
50 [GO] 2020―Sep―14 Response of the multiple sclerosis community to COVID-19 Olga Ciccarelli, Jeffrey A Cohen, Alan Thompson
51 [GO] 2020―Sep―10 COVID-19 associated with encephalomyeloradiculitis and positive anti-aquaporin-4 antibodies: Cause or coincidence? - Commentary Cristina Valencia-Sanchez, Eoin P Flanagan
52 [GO] 2020―Sep―10 COVID-19 associated with encephalomyeloradiculitis and positive anti-aquaporin-4 antibodies: Cause or coincidence? Diogo Goulart Corrêa, Fabiana Cavalcanti de Souza Lima, Daniel da Cruz Bezerra, Antônio Carlos Coutinho, Luiz Celso Hygino da Cruz
53 [GO] 2020―Aug―17 MS, pregnancy and COVID-19 Charmaine Yam, Vilija Jokubaitis, Kerstin Hellwig, Ruth Dobson
54 [GO] 2020―Aug―10 Multiple sclerosis management during the COVID-19 pandemic Brandon P Moss, Kedar R Mahajan, Robert A Bermel, Kelsey Hellisz, Le H Hua, Timothy Hudec, et al. (+20)
55 [GO] 2020―Aug―07 COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual? Wallace J Brownlee
56 [GO] 2020―Aug―07 Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient Hannah Wurm, Kate Attfield, Astrid KN Iversen, Ralf Gold, Lars Fugger, Aiden Haghikia
57 [GO] 2020―Aug―07 COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment Rick Dersch, Thomas Wehrum, Sebastian Fähndrich, Monika Engelhardt, Sebastian Rauer, Benjamin Berger
58 [GO] 2020―Jul―14 COVID-19 in multiple sclerosis: The Dutch experience Floor C Loonstra, Elske Hoitsma, Zoé LE van Kempen, Joep Killestein, Jop P Mostert
59 [GO] 2020―Jul―14 COVID-19 in people with multiple sclerosis: A global data sharing initiative Liesbet M Peeters, Tina Parciak, Clare Walton, Lotte Geys, Yves Moreau, Edward De Brouwer, et al. (+42)
60 [GO] 2020―Jun―22 COVID-19 will change MS care forever - Commentary SC Krieger
61 [GO] 2020―Jun―22 COVID-19 will change MS care forever - No Paolo Preziosa, Maria A Rocca, Massimo Filippi
62 [GO] 2020―Jun―22 COVID-19 will change MS care forever - Yes Virginia Meca-Lallana
63 [GO] 2020―Jun―19 Keeping standards of multiple sclerosis care through the COVID-19 pandemic Jaume Sastre-Garriga, Mar Tintoré, Xavier Montalban
64 [GO] 2020―May―28 Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression Tiziana Carandini, Anna Margherita Pietroboni, Luca Sacchi, Milena Alessandra De Riz, Mattia Pozzato, Andrea Arighi, et al. (+4)
 [1] 

64 Results       Page 1


[de][en]

Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.004 sec